EP0542844A1 - 3-substituted piperidine derivatives - Google Patents

3-substituted piperidine derivatives

Info

Publication number
EP0542844A1
EP0542844A1 EP91914530A EP91914530A EP0542844A1 EP 0542844 A1 EP0542844 A1 EP 0542844A1 EP 91914530 A EP91914530 A EP 91914530A EP 91914530 A EP91914530 A EP 91914530A EP 0542844 A1 EP0542844 A1 EP 0542844A1
Authority
EP
European Patent Office
Prior art keywords
compound
pentylpiperidine
phenyl
alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91914530A
Other languages
German (de)
French (fr)
Inventor
Thomas Henry Smithkline Beecham Pharma. Brown
David Gwynn Smithkline Beecham Pharma. Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909017225A external-priority patent/GB9017225D0/en
Priority claimed from GB909021852A external-priority patent/GB9021852D0/en
Priority claimed from GB919107780A external-priority patent/GB9107780D0/en
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of EP0542844A1 publication Critical patent/EP0542844A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Definitions

  • the present invention relates to 3-substituted piperidine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
  • the present invention therefore provides, in a first aspect, compounds of structure (I) :
  • R is C 1 -8 alkyl (phenyl) p, C 2-8 alkenyl (phenyl) p,
  • p is 0 to 2 ;
  • n 0 to 6 ;
  • A is a bond, oxygen, sulphur or NR 1 ;
  • R 1 is hydrogen, C 1 -8 alkyl or phenylC 1-4 alkyl
  • n 0 to 3;
  • Ar is aryl or heteroaryl, each of which may be
  • R is C 1-8 alkyl(phenyl)p, C 2-8 alkenyl- (phenyl)p, C 2-8 alkynyl(phenyl)p, C 3-8 cycloalkyl or
  • R is C 1-8 alkyl(phenyl)p in which p is 0 or 1, i.e. C 1-8 alkyl, such as n-pentyl, or phenylC 1-8 alkyl such as phenylpropyl, or R is C 2-8 alkenyl(phenyl)p wherein p is 1, such as cinnamyl.
  • n is 0 to 6; preferably n is 0 to 3; most preferably n is 1.
  • m is 0 to 3; preferably m is 0 or 1; most preferably m is 0.
  • A is a bond, oxygen, sulphur or NR 1 ;
  • A is oxygen or sulphur; most preferably A is. oxygen.
  • A is oxygen
  • n is preferably 1 and m is preferably 0.
  • Ar is optionally substituted aryl or heteroaryl; preferably Ar is optionally substituted aryl.
  • Suitable aryl groups include, for example,
  • unsaturated monocyclic and unsaturated or partially saturated bicyclic ring systems of up to 10 carbon atoms, such as, for example, phenyl, naphthyl and
  • Suitable substituted phenyl rings include, for example, phenyl rings substituted by a C 1-2 alkylenedioxy group such as a 3,4-methylenedioxy group or by 1 to 3 substituents selected from halogen, C 1-4 alkoxy,
  • CN optionally substituted phenyl, optionally substituted phenylC 1-4 alkyl and optionally substituted phenylC 1-4 alkoxy.
  • Suitable optionally substituted phenylC 1-4 alkyl groups include, for example benzyl.
  • Suitable optionally substituted phenylC 1-4 alkoxy groups include, for example
  • Suitable substituents for said optionally substituted phenyl, phenylC 1-4 alkyl and phenylC 1-4 alkoxy groups include for example halogen, C 1-4 alkyl, C 1-4 alkoxy, nitro and trifluoromethyl groups.
  • Suitable heteroaryl rings include, for example, unsaturated monocyclic and unsaturated or partially saturated bicyclic ring systems of up to 10 carbon atoms containing at least one heteroatom, such as pyridyl, thienyl, guinolinyl, tetrahydroquinolinyl and imidazolyl rings. The heteroaryl ring can be linked to the
  • Suitable substituents for said heteroaryl rings include, for example, 1 to 3 substituents selected from halogen, C 1-4 alkyl and C 1-4 alkoxy.
  • Alkyl groups present in the compounds of structure (I), alone or as part of another group, can be straight or branched. It will be appreciated that for use in medicine a salt of a compound (I) should be pharmaceutically
  • salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically acceptable inorganic or organic acid addition salts.
  • Other nonpharmaceutically acceptable salts may be used for
  • Particular compounds of the invention include:
  • structure (I) may contain one or more asymmetric centres, in particular at the 3-position of the piperidine ring. Such compounds will exist as optical isomers
  • the compounds of the present invention can be prepared by processes analogous to those known in the art.
  • the present invention therefore provides in a further aspect, a process for the preparation of a compound of structure (I) which comprises:
  • R and n are as described for structure (I) and A 1 is O, S or NR 1 , with a compound of structure
  • R, A, Ar m and n are as hereinbefore defined and x ⁇ is a counter ion; and optionally thereafter forming a salt.
  • fluoro-substituted aryl compound F-Ar is employed in process (a), the reaction is effected in the presence of a strong base such as sodium hydride, and in an inert organic solvent such as dimethylformamide.
  • a strong base such as sodium hydride
  • an inert organic solvent such as dimethylformamide.
  • the aryl group is substituted by an activating group such as CF 3 or NO 2 .
  • a 1 is oxygen or sulphur the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine.
  • Such a reaction is known as the Mitsunobu reaction (as described in Synthesis 1981, 1).
  • the leaving group L 1 may be for example a halogen atom or a sulphonyloxy group eg. methanesulphonyloxy or p-toluene sulphonyloxy.
  • the reaction may be effected in the presence or absence of solvent and at temperature in the range 0 to 200oC.
  • the reduction of a compound of structure (IV) can be effected by methods known in the art, for example using a reducing agent such as lithium aluminium hydride.
  • a compound of structure (IV) can be prepared (for example as described below) and reduced in a
  • reaction of a compound of structure (VI) with RL 2 according to process (e) may be effected in
  • the leaving group L 2 may be for example a halide such as bromide or chloride, an acyloxy group such as acetoxy or chloroacetoxy or a sulphonyloxy group such as methanesulphonyloxy or p-toluenesulphonyloxy.
  • L 2 is a halide
  • reaction is preferably carried out in the presence of a weak base such as potassium carbonate, and when L 2 is sulphonyloxy, a strong base such as sodium hydride or potassium t-butoxide may be employed.
  • a weak base such as potassium carbonate
  • a strong base such as sodium hydride or potassium t-butoxide
  • Reduction of a compound of formula (VII) may be effected using standard reducing agents such as lithium aluminium hydride.
  • Reduction of a compound of formula (VIII) may be effected for example by hydrogenation, using a noble metal catalyst such as platinum, palladium or platinum oxide, suitably in a solvent such as an alcohol eg.
  • a noble metal catalyst such as platinum, palladium or platinum oxide
  • the compounds of structure (II) can be prepared from the corresponding compounds in which R is hydrogen, by alkylation under standard conditions.
  • compounds of structure (II) in which R is n-pentyl can be prepared from the corresponding precursor in which R is hydrogen by reaction with an n-pentylhalide such as n-pentyl bromide in a suitable solvent, such as methyl ethyl ketone, or a C 1-4 alkanol such as ethanol, in the presence of a base, such as potassium carbonate, or dimethylformamide in the presence of an iodoalkane.
  • a suitable solvent such as methyl ethyl ketone
  • a C 1-4 alkanol such as ethanol
  • the corresponding compounds of structure (II) in which R is hydrogen are available commercially, known in the literature or can be prepared by standard techniques; for example by reduction of the corresponding 3-hydroxyalkylpyridine.
  • the compounds of structure (II) in which A 1 is oxygen can be prepared by reduction of a compound of structure (IX): in which R and n are as described for structure (I) and X- is a counter ion.
  • halogen atom, or a mesyloxy or tosyloxy group can be prepared from the corresponding alcohol in conventional manner.
  • R 4 represents -(CH 2 ) n-1 CO 2 H or an activated
  • the carboxylic acid may itself be prepared for example by oxidation of the corresponding alcohol, ie. a compound of structure (II) wherein A 1 is oxygen.
  • Compounds of structure (V) may be prepared in analogous manner to compounds of structure (III); where necessary the chain length may be increased using methods well known in the art.
  • Suitable protecting groups include aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl and acyl groups such as acetyl, trifluoroacetyl, benzoyl,
  • benzyloxycarbony1 methoxycarbonyl, ethoxycarbonyl, or benzyloxycarbony1.
  • An aralkyl group such as benzyl may be cleaved by
  • a compound of formula (VII) may be prepared by reaction of a compound of formula (VI) with an
  • appropriate acid derivative for example an acid chloride, or anhydride.
  • a compound of structure (VIII) may be prepared using the general methods described in processes (a) to (e) above. When compounds of structure (I) are obtained as mixtures of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.
  • the compounds of the invention have been found to exhibit high calcium influx blocking activity and as such are expected to be of use in therapy in treating
  • the compounds are expected to be of use in the treatment of anoxia, ischaemia including for example stroke, migraine, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction withdrawal.
  • a method of treatment of conditions or diseases caused or exacerbated by the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of structure (I) or a
  • the present invention also provides a method of treatment of anoxia, ischaemia including for example stroke, migraine, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction
  • the compounds of the present invention are usually administered in a standard
  • compositions comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof and a
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water
  • suspending agent preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be
  • Such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable
  • compositions for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • Compounds of the invention may also be administered parenterally, by bolus injection or continuous
  • Typical parenteral compositions consist of a solution or suspension of the compound or
  • a pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • composition is in unit dose form such as a tablet or capsule.
  • Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral
  • administration contains preferably from 0.1 to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
  • the compounds of the invention may be administered by continuous intravenous infusion, preferably at a dose of up to 100mg per day.
  • the compounds will be administered for a period of continuous therapy, for examele for a week or more.
  • the pipette (internal solution) contained in mM: CsCl, 130; HEPES, 10; EGTA, 10; MgCl 2 , 4; ATP, 2; buffered to pH 7.2 with CsOH.
  • Peak voltage gated Ca 2+ channel currents of up to 10 nA from dorsal root ganglion neurons were recorded using 10 mM Ba 2+ as charge carrier. Currents were evoked from 3. holding potential of -80 mV to a test potential of 0 or +10 mV every 15 seconds. This test potential was at the peak of the current voltage
  • Compound of structure (I) 0.1 - 60 mg sodium hydroxide or hydrochloric acid to pH ca 7 polyethylene glycol 0 - 2.5 ml alcohol 0 - 2.5 ml water to 5 ml
  • a toxicity adjusting agent eg. sodium chloride, dextrose or mannitol may also be added.
  • the title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylpiperidine (1.85g), 3-trifluoromethylphenol (1.62g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.41g), m.p. 165°C.
  • the title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.0g), 4-cyanophenol (1.19g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (0.79g), m.p. 104°C.
  • the title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.0g), phenol (0.94g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (1.02g), m.p. 144.5°C.
  • the title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.00g), 3,4-dichlorophenol (1.63g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (1.10g), m.p.188-190°C.
  • the title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.00g), 4-iso-propylphenol (1.36g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.18g), m.p.172-174°C.
  • the title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (1.5g), 3-iso-propylphenol (1.1g), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.8g), m.p.138-140°C.
  • the title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (1.50g), 4-tert-butylphenol (1.22g), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.205g), m.p.197-199°C.

Abstract

Composés de la structure (I) dans laquelle R représente C1-8 alkyle(phényle)p, C2-8 alcényle(phényle)p, C2-8 alcynyle(phényle)p, C3-8 cycloalkyle ou C1-8 alkyle C3-8 cycloalkyle, p est 0 à 2; n est 0 à 6; A représente une liaison, oxygène, soufre ou NR1; R1 représente hydrogène, C1-8 alkyle ou phényle C1-4 alkyle; m est 0 à 3; et Ar est aryle ou hétéroaryle, chacun d'entre eux pouvant être éventuellement substitués, ainsi que leurs sels; procédés de préparation desdits composés (I), compositions pharmaceutiques qui les contiennent et leur utilisation en médecine, particulièrement comme agents de blocage du calcium.Compounds of structure (I) in which R represents C1-8 alkyl (phenyl) p, C2-8 alkenyl (phenyl) p, C2-8 alkynyl (phenyl) p, C3-8 cycloalkyl or C1-8 alkyl C3-8 cycloalkyl, p is 0 to 2; n is 0 to 6; A represents a bond, oxygen, sulfur or NR1; R1 represents hydrogen, C1-8 alkyl or phenyl C1-4 alkyl; m is 0 to 3; and Ar is aryl or heteroaryl, each of which may be optionally substituted, as well as their salts; processes for the preparation of said compounds (I), pharmaceutical compositions containing them and their use in medicine, particularly as calcium blocking agents.

Description

3-SUBSITUTED PIPERIDINE DERIVATIVES
The present invention relates to 3-substituted piperidine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
The present invention therefore provides, in a first aspect, compounds of structure (I) :
in which
R is C 1 -8alkyl (phenyl) p, C2-8alkenyl (phenyl) p,
C2-8alkynyl (phenyl) p, C3-8cycloalkyl or
C1 -8alkylC3 -8cycloalkyl;
p is 0 to 2 ;
n is 0 to 6 ;
A is a bond, oxygen, sulphur or NR1;
R1 is hydrogen, C1 -8alkyl or phenylC1-4alkyl;
m is 0 to 3; and
Ar is aryl or heteroaryl, each of which may be
optionally substituted,
and salts thereof. Suitably, R is C1-8alkyl(phenyl)p, C2-8alkenyl- (phenyl)p, C2-8alkynyl(phenyl)p, C3-8cycloalkyl or
C1-8alkylC3-8cycloalkyl. It will be understood that the alkylcycloalkyl, alkylphenyl, alkenylphenyl and alkynylphenyl groups are linked to the piperidine nitrogen atom via the alkyl, alkenyl and alkynyl moieties respectively. Preferably R is C1-8alkyl(phenyl)p in which p is 0 or 1, i.e. C1-8alkyl, such as n-pentyl, or phenylC1-8alkyl such as phenylpropyl, or R is C2-8alkenyl(phenyl)p wherein p is 1, such as cinnamyl. Suitably, n is 0 to 6; preferably n is 0 to 3; most preferably n is 1.
Suitably, m is 0 to 3; preferably m is 0 or 1; most preferably m is 0.
Suitably, A is a bond, oxygen, sulphur or NR1;
preferably A is oxygen or sulphur; most preferably A is. oxygen. When A is oxygen n is preferably 1 and m is preferably 0.
Suitably, Ar is optionally substituted aryl or heteroaryl; preferably Ar is optionally substituted aryl.
Suitable aryl groups include, for example,
unsaturated monocyclic and unsaturated or partially saturated bicyclic ring systems of up to 10 carbon atoms, such as, for example, phenyl, naphthyl and
tetrahydronaphthyl. Preferred are optionally
substituted phenyl rings.
Suitable substituted phenyl rings include, for example, phenyl rings substituted by a C1-2alkylenedioxy group such as a 3,4-methylenedioxy group or by 1 to 3 substituents selected from halogen, C1-4alkoxy,
nitro, SC1-4alkyl, NR2R2 (in which each R2 group
can be H or C1-4alkyl), OCF3, C1-6alkyl,
trifluoromethyl, CN, optionally substituted phenyl, optionally substituted phenylC1-4alkyl and optionally substituted phenylC1-4alkoxy. Preferred are phenyl rings substituted by one or two substituents, in
particular, by a single halogen, trifluoromethyl,
unsubstituted phenyl or unsubstituted phenylC1-4alkoxy group; or by two chloro atoms especially in the 3- and 4-positions of the phenyl ring. Suitable optionally substituted phenylC1-4alkyl groups include, for example benzyl. Suitable optionally substituted phenylC1-4alkoxy groups include, for
example benzyloxy groups. Suitable substituents for said optionally substituted phenyl, phenylC1-4alkyl and phenylC1-4alkoxy groups include for example halogen, C1-4alkyl, C1-4alkoxy, nitro and trifluoromethyl groups. Suitable heteroaryl rings include, for example, unsaturated monocyclic and unsaturated or partially saturated bicyclic ring systems of up to 10 carbon atoms containing at least one heteroatom, such as pyridyl, thienyl, guinolinyl, tetrahydroquinolinyl and imidazolyl rings. The heteroaryl ring can be linked to the
remainder of structure (I) via a carbon atom or via a hetero atom, e.g. a nitrogen atom.
Suitable substituents for said heteroaryl rings include, for example, 1 to 3 substituents selected from halogen, C1-4alkyl and C1-4alkoxy. Alkyl groups present in the compounds of structure (I), alone or as part of another group, can be straight or branched. It will be appreciated that for use in medicine a salt of a compound (I) should be pharmaceutically
acceptable. Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically acceptable inorganic or organic acid addition salts. Other nonpharmaceutically acceptable salts may be used for
example as intermediates and are included within the scope of this invention.
Particular compounds of the invention include:
3-(4-fluorophenoxymethy1)-1-pentyIpiperidine oxalate,
3-(3,4-methylenedioxyphenoxymethyl)-1-pentylpiperidine hydrochloride,
3-(3-trifluoromethylphenoxymethyl)-1-pentylpiperidine hydrochloride,
3-(3-phenylphenoxymethyl)-1-pentylpiperidine oxalate,
3-(2-phenylphenoxymethyl)-1-pentylpiperidine oxalate, 3-(4-phenylphenoxymethyl)-1-pentylpiperidine oxalate,
3-(2-benzylphenoxymethyl)-1-pentylpiperidine oxalate,
3-(4-benzylphenoxymethyl)-1-pentylpiperidine
hydrochloride,
3-(4-benzyloxyphenoxymethyl)-1-pentyIpiperidine
hydrochloride,
1-cinnamyl-3-(3,4-dichlorophenoxymethyl)piperidine oxalate,
3-(4-iso-propylphenoxymethyl)-1-pentylpiperidine
hydrochloride, and
3-(3,4-dichlorophenylaminomethyl)-1-pentyIpiperidine dihydrochloride.
It will be appreciated that the compounds of
structure (I) may contain one or more asymmetric centres, in particular at the 3-position of the piperidine ring. Such compounds will exist as optical isomers
(enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the invention. Further, all diastereomeric forms possible (pure
enantiomers and mixtures thereof) are within the scope of the invention.
The compounds of the present invention can be prepared by processes analogous to those known in the art. The present invention therefore provides in a further aspect, a process for the preparation of a compound of structure (I) which comprises:
(a) for compounds of structure (I) in which A is O, S or
NR1, reaction of a compound of structure (II):
in which R and n are as described for structure (I) and A1 is O, S or NR1, with a compound of structure
L(CH2)mAr in which m and Ar are as described for
structure (I), and L is a leaving group;
(b) for compounds of structure (I) in which A is O, s or
NR1, reaction of a compound of structure (III): in which n and R are as described for structure (I) and L1 is a group displaceable by a nucleophile, with a compound of structure HA1(CH2)mAr where m and Ar
are as described for structure (I) and A1 is as
described for structure (II); or (c) for compounds of structure (I) in which A is NR1, reduction of a compound of structure (IV) :
in which R4 represents the group
and n, m, R and Ar are as described for structure (I);
(d) for compounds of structure (I) in which A is a bond, reaction of a compound of structure (V) :
(wherein R, L1, m and n are as hereinbefore defined). with a compound of structure X1Ar in which Ar is as described for structure (I), and X1 is an alkali metal; (e) introduction of the group R into a compound of formula (VI) :
by reaction with a compound RL2, wherein L2 is a leaving group;
(f) Reduction of a compound of formula (VII) : wherein R5 is C1-7alkyl (phenyl) p, C2-7alkenyl (phenyl) p, C2-7alkynyl (phenyl) p or C1-7alkylC3-8cycloalkyl;
(g) Reduction of a compound of structure (VIII):
wherein R, A, Ar m and n are as hereinbefore defined and x⊝ is a counter ion; and optionally thereafter forming a salt.
In process (a) the reaction between a compound of structure (II) and a compound L(CH2)mAr can take
place under conditions which depend on the nature of the group L. For example, when L is halogen or a sulphonic acid residue such as a tosylate or mesylate, the reaction is carried out under standard conditions in a solvent, optionally in the presence of a base. When a
fluoro-substituted aryl compound F-Ar is employed in process (a), the reaction is effected in the presence of a strong base such as sodium hydride, and in an inert organic solvent such as dimethylformamide. Preferably the aryl group is substituted by an activating group such as CF3 or NO2.
The reaction between a compound of structure (III) and a compound of structure HA1(CH2)mAr can take
place under conditions which depend on the nature of L1 and A. For example when L1 is hydroxy, m is O and
A1 is oxygen or sulphur the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine. Such a reaction is known as the Mitsunobu reaction (as described in Synthesis 1981, 1).
Alternatively the leaving group L1 may be for example a halogen atom or a sulphonyloxy group eg. methanesulphonyloxy or p-toluene sulphonyloxy. In this case the reaction may be effected in the presence or absence of solvent and at temperature in the range 0 to 200ºC.
The reduction of a compound of structure (IV) can be effected by methods known in the art, for example using a reducing agent such as lithium aluminium hydride.
Conveniently a compound of structure (IV) can be prepared (for example as described below) and reduced in a
'one-pot' reaction, without isolation of compound (IV) itself.
The reaction between a compound of structure (V) and a compound of structure X1Ar can take place under
standard conditions known to those skilled in the art for the formation of carbon-carbon bonds.
The reaction of a compound of structure (VI) with RL2 according to process (e) may be effected in
conventional manner, for example in an organic solvent, such as dimethyl formamide. The leaving group L2 may be for example a halide such as bromide or chloride, an acyloxy group such as acetoxy or chloroacetoxy or a sulphonyloxy group such as methanesulphonyloxy or p-toluenesulphonyloxy. When L2 is a halide the
reaction is preferably carried out in the presence of a weak base such as potassium carbonate, and when L2 is sulphonyloxy, a strong base such as sodium hydride or potassium t-butoxide may be employed.
Reduction of a compound of formula (VII) may be effected using standard reducing agents such as lithium aluminium hydride.
Reduction of a compound of formula (VIII) may be effected for example by hydrogenation, using a noble metal catalyst such as platinum, palladium or platinum oxide, suitably in a solvent such as an alcohol eg.
ethanol.
The compounds of structure (II) can be prepared from the corresponding compounds in which R is hydrogen, by alkylation under standard conditions. For example, compounds of structure (II) in which R is n-pentyl can be prepared from the corresponding precursor in which R is hydrogen by reaction with an n-pentylhalide such as n-pentyl bromide in a suitable solvent, such as methyl ethyl ketone, or a C1-4alkanol such as ethanol, in the presence of a base, such as potassium carbonate, or dimethylformamide in the presence of an iodoalkane.
The corresponding compounds of structure (II) in which R is hydrogen are available commercially, known in the literature or can be prepared by standard techniques; for example by reduction of the corresponding 3-hydroxyalkylpyridine. Alternatively, the compounds of structure (II) in which A1 is oxygen can be prepared by reduction of a compound of structure (IX): in which R and n are as described for structure (I) and X- is a counter ion.
Compounds of structure (III) wherein L1 is OH can be prepared as described for compounds of structure (II), and compounds of structure (III) wherein L1 is a
halogen atom, or a mesyloxy or tosyloxy group can be prepared from the corresponding alcohol in conventional manner.
Compounds of structure (IV) wherein R4 is a group x can be prepared by
reacting a compound of structure (II) wherein A1
represents NR1 with an acylating agent corresponding to the group -(CH2)mAr, for example an acid chloride
ClOC(CH2)m-1 Ar.
Compounds of structure (IV) wherein R4 is a group may be prepared for
example by reaction of a corresponding compound wherein
R4 represents -(CH2)n-1CO2H or an activated
derivative thereof such as an acid halide, ester or anhydride, with an amine of formula HN(R1) (CH2)m
Ar. It will be appreciated that when the acid itself is employed, reaction with the amine should be effected in the presence of a coupling agent. The carboxylic acid may itself be prepared for example by oxidation of the corresponding alcohol, ie. a compound of structure (II) wherein A1 is oxygen.
Compounds of structure (V) may be prepared in analogous manner to compounds of structure (III); where necessary the chain length may be increased using methods well known in the art.
Compounds of structure (VI) may be prepared for example according to any of processes (a) to (d) above, using intermediates analogous to structures (II) to (IV) wherein R is replaced by an N-protecting group, which is subsequently removed by methods well known in the art.
Suitable protecting groups include aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl and acyl groups such as acetyl, trifluoroacetyl, benzoyl,
methoxycarbonyl, ethoxycarbonyl, or benzyloxycarbony1. An aralkyl group such as benzyl may be cleaved by
hydrogenolysis, and an acyl group such as benzoyl may be cleaved by hydrolysis. It will be appreciated that where the N-protecting group is aralkyl, the compound is of structure (I) and this reaction sequence thus provides a means of converting one compound of formula (I) into a different compound of formula (I).
A compound of formula (VII) may be prepared by reaction of a compound of formula (VI) with an
appropriate acid derivative for example an acid chloride, or anhydride.
A compound of structure (VIII) may be prepared using the general methods described in processes (a) to (e) above. When compounds of structure (I) are obtained as mixtures of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.
The compounds of the invention have been found to exhibit high calcium influx blocking activity and as such are expected to be of use in therapy in treating
conditions and diseases related to an accumulation of calcium in the brain cells of mammals, in particular humans. For example, the compounds are expected to be of use in the treatment of anoxia, ischaemia including for example stroke, migraine, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction withdrawal. In a further aspect of the invention there is therefore provided a method of treatment of conditions or diseases caused or exacerbated by the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of structure (I) or a
pharmaceutically acceptable salt thereof. In addition, the present invention also provides a method of treatment of anoxia, ischaemia including for example stroke, migraine, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction
withdrawal, which comprises administering to a subject in need thereof, an effective amount of a compound of structure (I) or a pharmaceutically acceptable salt thereof.
In therapeutic use, the compounds of the present invention are usually administered in a standard
pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof and a
pharmaceutically acceptable carrier or excipient.
The compounds of structure (I) and their
pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges. A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a
suspending agent, preservative, flavouring or colouring agent.
A composition in the form of a tablet can be
prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable
pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Compounds of the invention may also be administered parenterally, by bolus injection or continuous
infusion. Typical parenteral compositions consist of a solution or suspension of the compound or
pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
Preferably the composition is in unit dose form such as a tablet or capsule.
Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral
administration contains preferably from 0.1 to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Alternatively the compounds of the invention may be administered by continuous intravenous infusion, preferably at a dose of up to 100mg per day. Suitably the compounds will be administered for a period of continuous therapy, for examele for a week or more.
DATA
Ca2+ Current Measurement Cell preparations
Sensory neurons from dorsal root ganglia were dissociated from 1 day old rat pups (Forda et al.
Developmental Brain Research, 22 (1985), 55-65). Cells were plated out onto glass coverslips and used within 3 days to permit effective voltage clamp of Ca2+ currents.
Solutions
The pipette (internal solution) contained in mM: CsCl, 130; HEPES, 10; EGTA, 10; MgCl2, 4; ATP, 2; buffered to pH 7.2 with CsOH.
Cells were bathed in a normal Tyrodes solution before establishment of whole cell recording when the bathing solution was changed to one allowing isolation of Ca2+ currents.
The external solution for recording Ca2+ channel currents contained in mM: BaCl2, 10; TEA-Cl, 130;
glucose, 10; HEPES, 10; MgCl2, 1; buffered to pH 7.3 with TEA-OH. Barium was used as the charge carrier as this assists in current isolation and calcium dependent inactivation of current is avoided.
Compounds were dissolved in DMSO to make a 20 mM stock solution. At the drug concentration used the vehicle (0.1%) had no significant effect on Ca2+
currents.
All experiments were performed at 21 to 24°C.
Whole cell currents were recorded using List EPC-7 amplifiers and stored, digitised for later analysis using PC based software similar to that described previously (Benham & Tsien, Journal of Physiology (1988), 404.
767-784). RESULTS
Ca2+ currents
Peak voltage gated Ca2+ channel currents of up to 10 nA from dorsal root ganglion neurons were recorded using 10 mM Ba2+ as charge carrier. Currents were evoked from 3. holding potential of -80 mV to a test potential of 0 or +10 mV every 15 seconds. This test potential was at the peak of the current voltage
relationship and assessing block at this point reduced any errors due to drifting holding potential. Some cells showed slow rundown of current as is commonly seen when recording Ca2+ currents. The rundown rate was measured in control conditions and extrapolated through the time of drug application to derive a control value to relate the drug affected current to. Block by 20 μM drug was assessed 3 minutes after drug application.
Compounds of the invention gave percentage
inhibition of plateau Ca2+ current in the range 30 to 100%.
PHARMACEUTICAL FORMULATIONS
1. Formulation for intravenous infusion
Compound of structure (I) 0.1 - 60 mg
Sodium hydroxide/hydrochloric acid to pH ca 7 polyethylene glycol 0 - 30 ml propylene glycol 0 - 30 ml alcohol 0 - 10 ml water to 100 ml
2. Formulation for bolus injection
Compound of structure (I) 0.1 - 60 mg sodium hydroxide or hydrochloric acid to pH ca 7 polyethylene glycol 0 - 2.5 ml alcohol 0 - 2.5 ml water to 5 ml A toxicity adjusting agent eg. sodium chloride, dextrose or mannitol may also be added.
3. Tablet for oral administration mg/tablet
Compound of structure (I) 25 lactose 153 starch 33 crospovidone 12
microcrystalline cellulose 30 magnesium stearate 2
255 EXAMPLES
Intermediate Preparations
(i) 3-(Hydroxymethyl)-1-pentylpiperidine
A mixture of 3-(hydroxymethyl)piperidine (20g), 1- bromopentane (26.28g), potassium carbonate (24g) and ethanol (400ml) was heated at reflux for 4 days. The solution was filtered, and the solvent removed under reduced pressure. The residue was treated with acetone, filtered, the solvent removed and the resulting oil was distilled under reduced pressure to give the title compound as an oil. (24.63g, b.p. 103-104°C @ 0.3mmHg.)
(ii) 3-(Hydroxymethyl)-1-propylpiperidine
A mixture of 3-(hydroxymethyl)piperidine (20g), 1-bromopropane (21.4g), potassium carbonate (24g) and ethanol (400ml) was heated at reflux for 1 days. The solution was filtered, and the solvent removed under reduced pressure. The residue was treated with acetone, filtered, the solvent removed and the resulting oil distilled under reduced pressure to give the title compound as an oil. (18.21 g, b.p. 101-103°C @ 0.2mmHg.)
(iii) 1-Cinnamyl-3-(hydroxymethyl)piperidine A mixture of 3-(hydroxymethyl)piperidine (28g), cinnamyl bromide (47.91g), potassium carbonate (33.6g) and ethanol (300ml) was heated at reflux for 2 days. The solution was filtered, and the solvent removed under reduced pressure. The residue was distilled under reduced pressure to give the title compound as an oil. (24.63g, b.p. 164-168 °C @ 0.3mmHg.)
Found: C, 77.59; H, 9.18; N, 5.94%
(C15H21NO) requires: C, 77.88; H, 9.15; N, 6.05% (iv) 3-Methanesulphonyloxymethyl-1-pentylpiperidine hydrochloride
Methanesulphonyl chloride (5.8ml) in dichloromethane
(20ml) was added to a solution of 3-hydroxymethyl-1-pentylpiperidine (10g) in dichloromethane (20ml). The mixture was stirred for 18 hours, treated with hydrogen chloride in ether and recrystallised from ethylacetate to give the title compound (13.2g) m.p. 99-101°C (v) 3-(3-Hydroxypropyl)-1-pentylpyridinium bromide
A solution of 3-(3-hydroxypropyl)pyridine (20g), 1-bromopentane (22.05g) and acetone (250ml) was refluxed for 72 hours, cooled and poured into diethylether (200ml).
The oil which precipitated was collected by decantation then washed by decantation with diethyl ether (5 X 100ml) and dried at 50°C (0.1mmHg) to give the title compound (42g) which was used without further purification. (vi) 3-(3-Hydroxypropyl)-1-pentylpiperidine A mixture of 3-(3-hydroxypropyl)-1-pentylpyridinium bromide (42.g), platinum oxide (1.5g) and ethanol (350ml) was shaken under an atmosphere of hydrogen at 50 p.s.i. for 1 hour. The mixture was filtered and the solvent removed. The residue was dissolved in dilute sodium hydroxide (70ml) and extracted with dichloromethane (3 x 75ml). The organic extracts were combined, dried over magnesium sulphate and the solvent was removed to give the title compound as an oil (18.0g).
Example 1
3-(4-Fluorophenoxymethyl)-1-pentylpiperidine oxalate A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), 4-fluorophenol (1.21g) and triphenylphosphine (2.62g) in tetrahydrofuran (40ml) was treated with diethyl
azodicarboxylate (1.74g) in tetrahydrofuran (10ml). The resulting solution was stirred at room temperature for 18 hours, the solvent was removed and the residue was
chromatographed on silica gel eluted with
methanol/dichloromethane. The resulting oil was dissolved in ethyl acetate (50ml) and treated with oxalic acid
(0.62g). The precipitate was collected by filtration and recrystallised (methanol/ethyl acetate) to give the title compound (1.21g), m.p. 126 - 128°C.
Found: C, 61.17; H, 7.79; N, 3.78; F 4.71%.
(C17H26FNO . C2H2O4 . 3H2O) requires : C, 60 . 80 ; H, 7 . 60 ;
N, 3. 70; F, 5. 06% . Example 2
3-(3,4-Methylenedioxyphenoxymethyl)-1-pentylpiperidine hydrochloride
A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), sesamol (1.49g) and triphenylphosphine (2.62g) in
tetrahydrofuran (50ml) was treated with diethyl
azodicarboxylate (1.74g) in tetrahydrofuran (10ml). The resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil was dissolved in ethyl acetate (50ml) and treated with ethereal hydrogen chloride. The precipitate was collected by filtration and recrystallised
(methanol/ethyl acetate) to give the title compound
(1.01g), m.p. 183 - 184°C.
Found: C, 63.27; H, 8.22; N, 4.17; Cl, 10.37%.
(C18H27NO3.HCl) requires: C, 63.25; H, 8.20; N, 4.10;
Cl, 10.40%.
Example 3 3-(3-Phenylphenoxymethyl)-1-pentylpiperidine oxalate
A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), 3-phenylphenol (1.70g) and triphenylphosphine (2.62g) in tetrahydrofuran (40ml) was treated with diethyl
azodicarboxylate (1.66g) in tetrahydrofuran (50ml). The resulting solution was stirred at room temperature for 18 hours, the solvent was removed and the residue was chromatographed on silica gel eluted with
methanol/dichloromethane. The resulting oil (l.lg) was dissolved in ethyl acetate (50ml) and treated with oxalic acid (1.1equivalents). The precipitate was collected by filtration and recrystallised (methanol/ethyl acetate) to give the title compound (0.8g), m.p. 148 - 149°C.
Found: C, 70.46; H, 7.80; N, 3.24%.
(C23H31NO.C2H2O4) requires: C, 70.23; H, 7.78; N, 3.28%
Example 4
3-(2-Phenylphenoxymethyl)-1-pentylpiperidine oxalate A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), 2-phenylphenol (1.70g) and triphenylphosphine (2.62g) in tetrahydrofuran (50ml) was treated with diethyl
azodicarboxylate (1.74g) in tetrahydrofuran (10ml). The resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil was dissolved in ethyl acetate (50ml) and treated with oxalic acid (0.9g). The precipitate was collected by filtration and recrystallised (methanol/ethyl acetate) to give the title compound (1.10g),
m.p. 99 - 101°C.
Found: C, 70.00; H, 7.97; N, 3.28%
(C23H31N0.C2H2O4) requires: C, 70.23; H, 7.78; N, 3.28% Example 5
3-(4-Benzyloxyphenoxymethyl)-1-pentylpiperidine
hydrochloride
A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), 4-benzyloxyphenol (2.0g) and triphenylphosphine (2.62g) in tetrahydrofuran (50ml) was treated with diethyl
azodicarboxylate (1.74g) in tetrahydrofuran (10ml). The resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil was dissolved in ethyl acetate and treated with hydrogen chloride in diethyl ether. The precipitate was collected by filtration and recrystallised
(methanol/ethyl acetate) to give the title compound
(0.5g), m.p. 149 - 150°C.
Found: C, 71.56; H, 8.71; N, 3.43; Cl, 8.57%
(C24H33NO2.HCl) requires: C, 71.35; H, 8.48; N, 3.47;
Cl, 8.78%
Example 6 3-(4-Benzylphenoxymethyl)-1-pentylpiperidine hydrochloride
The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), 4-hydroxydiphenylmethane (1.84g), triphenylphosphine (2.62g) and diethyl azodicarboxylate
(1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.51g), m.p. 169 - 171°C.
Found: C, 74.38; H, 8.96; N, 3.68; Cl, 8.22%
(C24H33NO.HCI) requires: C, 74.30; H, 8.83; N, 3.61;
Cl, 9.16%
Example 7 3-(3-Trifluoromethylphenoxymethyl)-1-pentylpiperidine hydrochloride
The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylpiperidine (1.85g), 3-trifluoromethylphenol (1.62g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.41g), m.p. 165°C.
Found: C, 59.04; H, 7.40; N, 3.91; Cl, 9.67%
(C18H26F3NO.HCl) requires: C, 59.0; H, 7.4; N, 3.8;
Cl, 9.7% Example 8
3-(4-Nitrophenoxymethyl)-1-pentylpiperidine hydrochloride
The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylpiperidine (1.85g), 4-nitrophenol (1.39g),
triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.13g), m.p. 220°C.
Found: C, 59.22; H, 7.96; N, 8.08; Cl, 10.31%
(C17H26N2O3.HCl) requires: C, 59.55; H, 7.94; N, 8.17;
Cl, 10.35%
Example 9
3-(4-Phenylphenoxymethyl)-1-pentylpiperidine oxalate
The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), 4-phenylphenol (1.70g),
triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (0.60g), m.p. 173.5 - 174°C.
Found: C, 70.17; H, 7.74; N, 3.50%
(C23H31NO.C2H2O4) requires: C, 70.23; H, 7.78; N, 3.28%
Example 10
3-(2-Benzylphenoxymethyl)-1-pentylpiperidine oxalate
The title compound was prepared in a similar manner to example 5 starting from 3-hydroxymethyl-1-pentylpiperidine (2.0g), 2-hydroxydiphenylmethane (1.84g),
triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (0.260g), m.p. 120°C.
Found: C, 70.21; H, 7.99; N, 3.20%
(C24H33NO.C2H2O4.0.25H2O) requires: C, 69.94; H, 7.96; N, 3.14%
Example 11 3-(4-Chlorophenoxymethyl)-1-pentylpiperidine oxalate
The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.0g), 4-chlorophenol (1.28g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was
recrystallised from methanol/ethyl acetate (0.82g), m.p. 140°C. Found: C, 59.27; H, 7.26; N, 3.80; Cl, 8.93%
(C17H26ClNO.C2H2O4) requires: C, 59.14; H, 7.31; N, 3.63; Cl, 9.19%
Example 12
3-(4-Cyanophenoxymethyl)-1-pentylpiperidine oxalate
The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.0g), 4-cyanophenol (1.19g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (0.79g), m.p. 104°C.
Found: C, 63.83; H, 7.59; N, 7.47%
(C18H26N2O.C2H2O4) requires: C, 63.81; H, 7.50; N, 7.44%
Example 13
3-Phenoxymethyl-1-pentylpiperidine oxalate
The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.0g), phenol (0.94g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (1.02g), m.p. 144.5°C.
Found: C, 65.15; H, 8.43; N, 4.02%
(C17H27NO.C2H2O4) requires: C, 64.93; H, 8.32; N, 3.99%
Example 14
3-(4-Fluorobenzyloxymethyl)-1-pentylpiperidine oxalate A solution of 3-hydroxymethyl-1-pentylpiperidine (3.0g) in dimethylformamide (30 ml) was treated with sodium hydride (0.0162 mole) and then stirred for 0.5 hour when 4-fluorobenzyl chloride (2.35g) was added. The mixture was stirred for 2 days and the solvent removed. Water
(100 ml) and dichloromethane (100 ml) were added and the organic layer was separated, washed with saturated sodium chloride (150 ml) and dried over magnesium sulphate. The solvent was removed and the residue chromatographed on silica gel using methanol/dichloromethane as eluent. The resulting oil was dissolved in ethyl acetate and treated with oxalic acid (1.1 mole equivalent). The precipitate was collected by filtration and recrystallised
(methanol/ethyl acetate) to give the title compound
(1.2g), m.p. 126 - 127°C.
Found: C, 62.64; H, 7.97; N, 3.66%.
(C18H28FNO.C2H2O4) requires: C, 62.64; H, 7.89; N, 3.65%
Example 15
3-(3,4-Methylenedioxyphenoxymethyl)-1-propylpiperidine hydrochloride
The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-propylpiperidine (1.57g), sesamol (1.38g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.30g), m.p. 154°C. Found: C, 59.14; H, 7.63; N, 4.62; Cl, 10.77%
(C16H23NO3.HCl.0.5H2O) requires: C, 59.47; H, 7.74;
N, 4.34; Cl, 10.84% Example 16
1-Cinnamyl-3-(3,4-dichlorophenoxymethyl)piperidine oxalate The title compound was prepared in a similar manner to example 1 from 1-cinnamyl-3-hydroxymethylpiρeridine
(2.00g), 3,4-dichlorophenol (1.41g), triphenylphosphine (2.27g) and diethyl azodicarboxylate (1.51g). Treating the product with oxalic acid in ethyl acetate gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (1.27g), m.p.206°C.
Found: C, 59.37; H, 5.46; N, 3.16; Cl, 15.16%
(C21H23Cl2NO.C2H2O4) requires: C, 59.24; H, 5.40; N, 3.00; Cl, 15.16%
Example 17
1-Cinnamyl-3-(4-fluorophenoxymethyl)piperidine oxalate
The title compound was prepared in a similar manner to example 1 from 1-cinnamyl-3-hydroxymethylpiperidine
(2.00g), 4-fluorophenol (0.971g), triphenylphosphine
(2.27g) and diethyl azodicarboxylate (1.51g). Treating the product with oxalic acid in ethyl acetate gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.7g), m.p.123°C.
Found: C, 66.51; H, 6.31; N, 3.44%
(C21H24FNO.C2H2O4) requires: C, 66.49; H, 6.31; N, 3.37% Example 18
3-(3,4-Dichlorophenoxymethyl)-1-pentylpiperidine
hydrochloride
The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.00g), 3,4-dichlorophenol (1.63g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (1.10g), m.p.188-190°C.
Found: C, 55.92; H, 7.18; N, 3.86; Cl-, 9.64%
(C17H25Cl2NO.HCl) requires: C, 55.67; H, 7.15; N, 3.82; Cl-, 9.68%
Example 19 3-(4-iso-Propylphenoxymethyl)-1-pentylpiperidine
hydrochloride
The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.00g), 4-iso-propylphenol (1.36g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.18g), m.p.172-174°C.
Found: C, 70.41; H, 9.95; N, 4.34% (C20H33NO.HCl) requires: C, 70.66; H, 10.08; N, 4.12%
Example 20 3-(3-iso-Propylphenoxymethyl)-1-pentylpiperidine
hydrochloride
The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (1.5g), 3-iso-propylphenol (1.1g), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.8g), m.p.138-140°C.
Found: C, 69.89; H, 9.91; N, 4.10; Cl-, 10.33%
(C20H33NO.HCl.0.25 H2O) requires: C, 69.74; H, 9.95; N, 4.07; Cl-, 10.29% Example 21
3-(3-tert-Butylphenoxymethyl)-1-pentylpiperidine
hydrochloride
The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (1.50g), 3-tert-butylphenol (1.22g), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (1.035g), m.p.185-187°C. Found: C, 71.39; H, 10.33; N, 4.09; Cl, 9.92%
(C21H35NO.HCl) requires: C, 71.26; H, 10.25; N, 3.96;
Cl,10.02%
Example 22
3-(4-Fluorobenzylaminomethyl)-pentylpiperidine
dihydrochloride
A mixture of 4-fluorobenzylamine (2.49g) and 3- methanesulphonyloxymethyl-1-pentylpiperidine hydrochloride (2g) was heated at 150°C for 2.5 hours. The mixture was dissolved in dichloromethane and the dichloromethane solution washed with dilute sodium hydroxide solution, dried over sodium sulphate and the solvent removed. The residue was chromatographed on silica gel with
dichloromethane - methanol as eluent and treated with hydrogen chloride in ether to give a solid.
Recrystallisation from ethyl acetate gave the title compound (0.92g), m.p. 207-209°C.
Found: C, 58.12; H, 8.55; N, 7.67; Cl, 19.41%
(C18H29FN2.2HCl.0.3H2O) requires: C, 58.26; H, 8.57; N, 7.54; Cl, 19.09%
Example 23
3-(4-Fluorophenylaminomethyl)-pentylpiperidine
dihydrochloride
Substituting 4-fluoroaniline for 4-fluorobenzylamine
(9.12g) in example 22 gave the title compound (0.593g) as a white microcrystaline solid, m.p. 196-198°C Found: C, 56.77; H, 8.12; N, 7.83; Cl, 19.63%
(C17H27FN2.2HCl.0.5H2O) requires: C, 56.66; H, 8.39; N, 7.77; Cl, 19.68%
Example 24
3-(3,4-Dichlorophenylaminomethyl)-pentylpiperidine dihydrochloride
Substituting 3,4-dichloroaniline for 4-fluorobenzylamine (4.04g) in example 22 gave the title compound (0.38g) as a white microcrystaline solid, m.p. 185-187°C
Found: C, 50.99; H, 7.02; N, 6.99%
(C17H26Cl2N2.2HCl) requires: C, 50.76; H, 7.02; N, 6.96%
Example 25 3-(4-tert-Butylphenoxymethyl)-1-pentylpiperidine
hydrochloride
The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (1.50g), 4-tert-butylphenol (1.22g), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.205g), m.p.197-199°C.
Found: C, 70.98; H, 10.21; N, 4.00; Cl, 9.82% (C21H35NO.HCl) requires: C, 71.26; H, 10.25; N, 3.96; Cl,10.02%
Example 26
3-[3-(4-Fluorophenoxy)propyl]-1-pentylpiperidine oxalate The title compound was prepared in a similar manner to example 1 from 1-pentyl-3-(3-hydroxypropyl)piperidine (2.13g), 4-fluorophenol (1.12g), triphenylphosphine
(2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (1.10g), m.p. 115 - 118°C. Found: C, 63.53; H, 8.11; N, 3.80%
(C19H30FNO.C2H2O4) requires: C, 63.48; H, 8.06; N, 3.53%
Example 27 3-[3-(3,4-Dichlorophenoxy)propyl]-1-pentylpiperidine oxalate
The title compound was prepared in a similar manner to example 1 from 1-pentyl-3-(3-hydroxypropyl)piperidine (2.13g), 3,4-dichlorophenol (1.63g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (0.5g), m.p. 127-130°C. Found: C, 56.35; H, 6.90; N, 3.25%
(C19H29Cl2NO.C2H2O4) requires: C, 56.25; H, 6.97; N, 3.12% Example 28 a) (-)-3-(4-Benzyloxyphenoxymethyl)-1-pentylpiperidine b) (+)-3-(4-Benzyloxyphenoxymethyl)-1-pentylpiperidine
The product from example 5 (55mg) was partitioned between diethyl ether and dilute sodium bicarbonate solution. The ether phase was separated, dried and the solvent removed. The residue was chromatographed on a Chiralcel OJ h.p.l.c. chromatography column using ethanol/hexane as eluent. The two enantiomers were collected. The (-) enantiomer being eluted first. Yield (8.0mg) rotation (-1.38° @ 22°C in methanol). The second peak gave the (+) enantiomer, yield (7.2mg) rotation (+1.24° @ 22°C in methanol).
Example 29
3-(3,4-Dichlorobenzylaminomethyl)-1-pentylpiperidine dihydrochloride
Substituting 3,4-dichlorobenzylamine for 4-fluorobenzylamine (0.587g) in example 22 gave the title compound (0.46g) as a white microcrystaline solid, m.p. 254-256°C Found: C, 51.55; H, 7.09; N, 6.73; Cl, 16.85%
(C18H28Cl2N2.2HCl) requires: C, 51.94; H, 7.26; N, 6.73; Cl, 17.04%

Claims

Claims:
1. A compound of structure (I):
in which
R is C1-8alkyl(phenyl)p, C2-8alkenyl(phenyl)p,
C2-8alkynyl(phenyl)p, C3-8cycloalkyl or
C1-8alkylC3-8cycloalkyl;
p is 0 to 2;
n is 0 to 6;
A is a bond, oxygen, sulphur or NR1;
R1 is hydrogen, C1-8alkyl or phenylC1-4alkyl;
m is 0 to 3; and
Ar is aryl or heteroaryl, each of which may be
optionally substituted,
or a salt thereof.
2. A compound according to claim 1 wherein R is C1-8alkyl, phenyl(C1-8) alkyl or phenyl(C2-8)alkenyl.
3. A compound according to claim 1 or claim 2 in which A is oxygen.
4. A compound according to any of claims 1 to 3 wherein n is 0 to 3.
5. A compound according to any of claims 1 to 4 wherein m is 0 to 3.
6. A compound according to any of claims 1 to 5 in which Ar is optionally substituted phenyl.
7. A compound according to claim 1 which is: 3-(4-fluorophenoxymethyl)-1-pentylpiperidine,
3-(3,4-methylenedioxyphenoxymethyl)-1-pentyIpiperidine, 3-(3-trifluoromethylphenoxymethyl)-1-pentylpiperidine, 3-(3-phenylphenoxymethyl)-1-pentylpiperidine,
3-(2-phenylphenoxymethyl)-1-pentylpiperidine,
3-(4-phenylphenoxymethyl)-1-pentylpiperidine,
3-(2-benzylphenoxymethyl)-1-pentylpiperidine,
3-(4-benzylphenoxymethyl)-1-pentylpiperidine,
3-(4-benzyloxyphenoxymethyl)-1-pentylpiperidine,
1-cinnamyl-3-(3,4-dichlorophenoxymethyl)piperidine,
3-(4-iso-propylphenoxvmethyl)-1-pentylpiperidine; or
3-(3,4-dichlorophenylaminomethyl)-1-pentyIpiperidine; or a pharmaceutically acceptable salt thereof.
8. A process for preparing a compound of structure (I) which comprises:
(a) for compounds of structure (I) in which A is O, S or NR1, reaction of a compound of structure (II):
in which R and n are as described for structure (I) and A1 is O, S or NR1, with a compound of structure
L(CH2)mAr in which m and Ar are as described for
structure (I), and L is a leaving group;
(b) for compounds of structure (I) in which A is O, S or
NR1, reaction of a compound of structure (III):
in which n and R are as described for structure (I) and L1 is a group displaceable by a nucleophile, with a compound of structure HA1(CH2)mAr where m and Ar
are as described for structure (I) and A1 is as
described for structure (II); or (c) for compounds of structure (I) in which A is NR1, reduction of a compound of structure (IV) :
in which R4 represents the group
and n, m, R and Ar are as described for structure (I);
(d) for compounds of structure (I) in which A is a bond, reaction of a compound of structure (V) :
(wherein R, L1, m and n are as hereinbefore defined). with a compound of structure X1Ar in which Ar is as described for structure (I), and X1 is an alkali metal;
(e) introduction of the group R into a compound of formula (VI) :
by reaction with a compound RL2, wherein L2 is a
leaving group; (f) Reduction of a compound of formula (VII)
wherein R5 is C1-7alkyl(phenyl)p, C2-7alkenyl(phenyl)p, C2-7alkynyl(phenyl)p or C1-7alkylC3-8cycloalkyl;
(g) Reduction of a compound of structure (VIII):
wherein R, A, Ar m and n are as hereinbefore defined and X⊝ is a counter ion; and optionally thereafter forming a salt.
9. A pharmaceutical composition comprising a compound of structure (I) as claimed in any of claims 1 to 7 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
10. A compound of structure (I) according to any of claims 1 to 7 or a pharmaceutically acceptable salt thereof for use in therapy.
11. Use of a compound of structure (I) according to any of claims 1 to 7 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of conditions caused or exacerbated by the accumulation of calcium in the brain cells of mammals.
12. A method of treatment of a condition caused or exacerbated by the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of structure (I) according to any of claims 1 to 7 or a pharmaceutically acceptable salt thereof.
13. A method according to claim 12 wherein the condition is stroke.
14. A method according to claim 12 or claim 13 wherein the mammal is a human.
EP91914530A 1990-08-06 1991-08-05 3-substituted piperidine derivatives Withdrawn EP0542844A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB909017225A GB9017225D0 (en) 1990-08-06 1990-08-06 Compounds
GB9017225 1990-08-06
GB909021852A GB9021852D0 (en) 1990-10-08 1990-10-08 Compounds
GB9021852 1990-10-08
GB9107780 1991-04-12
GB919107780A GB9107780D0 (en) 1991-04-12 1991-04-12 Compounds

Publications (1)

Publication Number Publication Date
EP0542844A1 true EP0542844A1 (en) 1993-05-26

Family

ID=27265217

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91914530A Withdrawn EP0542844A1 (en) 1990-08-06 1991-08-05 3-substituted piperidine derivatives

Country Status (14)

Country Link
EP (1) EP0542844A1 (en)
JP (1) JPH06500092A (en)
CN (1) CN1062349A (en)
AP (1) AP236A (en)
AU (1) AU649468B2 (en)
CA (1) CA2088490A1 (en)
IE (1) IE912760A1 (en)
IL (1) IL99074A0 (en)
MA (1) MA22251A1 (en)
MX (1) MX9100517A (en)
NZ (1) NZ239267A (en)
PT (1) PT98575A (en)
TW (1) TW239860B (en)
WO (1) WO1992002501A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290789A (en) * 1992-11-20 1994-03-01 Sterling Wintrop Inc. Penta and tetrasubstituted piperidines and compositions and method of treating psychosis
GB9226111D0 (en) * 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments
GB9314973D0 (en) * 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
WO1995024390A1 (en) * 1994-03-11 1995-09-14 Smithkline Beecham Plc Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
GB9411052D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Medicaments
AU713236B2 (en) * 1996-02-15 1999-11-25 Sankyo Company Limited Diarly alkane derivatives containing an alicyclic group, their preparation and their theraputic and prophylactic uses
US6110937A (en) * 1997-04-03 2000-08-29 Syntex Usa, Inc. Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain
CA2232147A1 (en) * 1997-04-03 1998-10-03 F. Hoffmann-La Roche Ag Phenoxymethyl piperidine derivatives
WO1999043658A1 (en) 1998-02-27 1999-09-02 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
CA2340341A1 (en) * 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
WO2004002483A1 (en) * 2002-06-27 2004-01-08 Actelion Pharmaceuticals Ltd Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease
EP3337788A4 (en) 2015-08-21 2019-03-27 Portola Pharmaceuticals, Inc. Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use
US10821106B2 (en) 2015-08-21 2020-11-03 Srx Cardio, Llc Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity
WO2017034990A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310762A1 (en) * 1975-05-16 1976-12-10 Roussel Uclaf NEW DERIVATIVES N-SUBSTITUTES OF PHENYL PIPERIDINE AND THEIR SALTS, METHOD OF PREPARATION AND APPLICATION AS MEDICINAL PRODUCTS
DE2950135A1 (en) * 1979-12-13 1981-06-19 Merck Patent Gmbh, 6100 Darmstadt BASIC AETHER, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND METHOD FOR THE PRODUCTION THEREOF
FR2510112A1 (en) * 1981-07-24 1983-01-28 Roussel Uclaf NOVEL DERIVATIVES OF 2-OXO-PYRID-3-YL OR PIPERIDIN-3-YL INDOLE, THEIR SALTS, PREPARATION METHOD, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING THE SAME
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
CA1260474A (en) * 1984-12-03 1989-09-26 Raymond A. Stokbroekx Benzoxazol- and benzothiazolamine derivatives
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
IL83275A (en) * 1986-09-08 1994-02-27 Novo Nordisk As Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them
EP0307141B1 (en) * 1987-09-10 1993-01-13 MERCK SHARP & DOHME LTD. Oxazoles and thiazoles for the treatment of senile dementia
FR2636946B1 (en) * 1988-09-23 1990-11-02 Lipha ((DIARYLMETHOXY) ALCOYL) -1 PYRROLIDINES AND PIPERIDINES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM
DE3834860A1 (en) * 1988-10-13 1990-04-19 Basf Ag HETEROCYCLICALLY SUBSTITUTED ALKOXYCUMARINES, METHOD FOR THE PRODUCTION THEREOF AND THERAPEUTIC AGENTS CONTAINING THEM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9202501A1 *

Also Published As

Publication number Publication date
AP9100314A0 (en) 1991-10-31
NZ239267A (en) 1994-05-26
MA22251A1 (en) 1992-04-01
AU649468B2 (en) 1994-05-26
AP236A (en) 1993-02-24
IE912760A1 (en) 1992-02-12
AU8324391A (en) 1992-03-02
MX9100517A (en) 1992-04-01
WO1992002501A1 (en) 1992-02-20
CN1062349A (en) 1992-07-01
CA2088490A1 (en) 1992-02-07
IL99074A0 (en) 1992-07-15
TW239860B (en) 1995-02-01
PT98575A (en) 1992-06-30
JPH06500092A (en) 1994-01-06

Similar Documents

Publication Publication Date Title
AP236A (en) "3-substituted piperdine derivatives, pharmaceutical compositions containing them and their use in therapy".
AP279A (en) 4 substituted piperidine derivatives, processes for their preparation pharmaceutical compositions containing them and their use in therapy.
EP0629190A1 (en) Compounds as calcium channel antagonists
DE69531154T2 (en) NEUROPROTECTIVE 3- (PIPERIDINYL-1) -CHROMAN-4,7-DIOL AND 1- (4-HYPHOXYPHENYL) -2- (PIPERIDINYL-1) -ALKANOL DERIVATIVES
WO1994013291A1 (en) Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives
AU5833494A (en) Piperidine derivatives as calcium channel antagonists
EP0589971A1 (en) Compounds
EP0711272A1 (en) Indane and tetrahydronaphthalene derivatives as calcium channel antagonists
WO1995003302A1 (en) Quinolizidines with calcium channel antagonistic activity
JP3645856B2 (en) Ethanesulfonyl-piperidine derivatives
EP0625981A1 (en) Azabicyclo compounds as calcium channel antagonists
JPS6337111B2 (en)
WO1995024390A1 (en) Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists
JPH09504014A (en) Amine derivatives as calcium channel antagonists
AU3959893A (en) N-aryloxy(thio)alkyl-azacycloalkanes useful as calcium channel antagonists
US4585785A (en) Cis and trans-3-aryloxy-4-hydroxypyrrolidines used as anti-arrhythmics
US5198451A (en) Heterocyclic carboxylic acids
AU703776B2 (en) Derivatives of 4-(cycloalkyl)piperidines and of 4-(cycloalkylalkyl)piperidines, their preparation and their therapeutic application
JP2961995B2 (en) Piperidine derivatives and antiarrhythmic drugs containing the same
JP3113447B2 (en) Aminocarboxylic acid derivatives, their production and use
JPH10500967A (en) Phenoxyalkyl-substituted piperidines, pyrrolidines, morpholines and thiomorpholines as calcium channel antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19960212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960625